KRAS and colorectal carcinoma: While previous studies have shown that PRMT5 inhibition leads to cell cycle arrest, the results of our cell cycle assay further show that following treatment with PRMT5 inhibitor, the KRAS mutant CRC cells showed a much greater level of G2 phase cell cycle arrest when compared to the KRAS WT CRC cells [26,38].